Mechanisms of resistance to EGFR targeted therapies

Cancer Biology and Therapy

Volumn 14, Issue 4, 2013, Pages 304-314

  Hrustanovic, Gorjan ^a,b   Lee, Bianca J ^a,b   Bivona, Trever G ^a,b  

^a Division of Hematology and Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EGFR; EGFR TKI; Erlotinib; Kinase; Lung cancer; Resistance; Targeted therapy

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BIM PROTEIN; CANERTINIB; CETUXIMAB; CO 1686; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NERATINIB; PANITUMUMAB; UNCLASSIFIED DRUG; WZ 4002;

APOPTOSIS; BINDING AFFINITY; CANCER CELL; CANCER RESISTANCE; CARCINOGENESIS; CELL STRUCTURE; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENOME; GLIOMA; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PARACRINE SIGNALING; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EGFR; EGFR TKI; ERLOTINIB; KINASE; LUNG CANCER; RESISTANCE; TARGETED THERAPY;

DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84875860054     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23627     Document Type: Review

References (134)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/ caac.20121.
2. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706-14; PMID:17762336; http://dx.doi.org/10.1097/JTO. 0b013e31812f3c1a.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108; PMID:15761078; http://dx.doi.org/10.3322/ canjclin. 55.2.74.
4. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10:760-74; PMID:20966921; http://dx.doi.org/10.1038/nrc2947.
5. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297:63-4; PMID:12098689; http://dx.doi.org/10.1126/science. 1073096.
6. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012; 13:287-97; PMID:22541616.
7. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19:2013-23; PMID:17681753; http://dx.doi.org/10.1016/j.cellsig.2007.06. 023.
8. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006; 42:17-23; PMID:16364841; http://dx.doi.org/10.1016/j. ejca.2005.07.031.
9. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118:257-62; PMID:16231326; http://dx.doi.org/10.1002/ijc.21496.
10. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7:169-81; PMID:17318210; http://dx.doi.org/10.1038/nrc2088.
11. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11:217-27; PMID:17349580; http://dx.doi.org/10.1016/j.ccr. 2006.12.017.
12. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137:1293-307; PMID:19563760; http://dx.doi.org/10.1016/j. cell.2009.04.025.
13. Thiel KW, Carpenter G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci U S A 2007; 104:19238-43; PMID:18042729; http://dx.doi.org/10.1073/pnas.0703854104.
14. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009; 34:641-51; PMID:19560417; http://dx.doi.org/10.1016/j. molcel.2009.04.034.
15. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57; PMID:19692680; http://dx.doi.org/10.1056/NEJMoa0810699.
16. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-8; PMID:20022809; http://dx.doi.org/10.1016/S1470- 2045(09)70364-X.
17. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-67; PMID:19692684; http://dx.doi.org/10.1056/NEJMoa0904554.
18. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2005; 2:e313; PMID:16187797; http://dx.doi.org/10.1371/journal.pmed. 0020313.
19. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97:1185-94; PMID:16106023; http://dx.doi.org/10.1093/jnci/dji238.
20. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-11; PMID:15329413; http://dx.doi.org/10.1073/pnas.0405220101.
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39; PMID:15118073; http://dx.doi.org/10.1056/NEJMoa040938.
22. Carter CA, Giaccone G. Treatment of nonsmall cell lung cancer: Overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol 2012; 24:123-9; PMID:22314615; http://dx.doi.org/10.1097/CCO.0b013e32834ec6a7.
23. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78; PMID:16467544; http://dx.doi.org/10.1056/ NEJMoa053422.
24. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834.
25. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369-85; PMID:16890793; http://dx.doi.org/10.1053/j. seminoncol.2006.04.003.
26. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008; 14:178-83; PMID:18536557; http://dx.doi.org/10.1097/PPO. 0b013e318172d71a.
27. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23; PMID:11255078; http://dx.doi.org/10.1016/S1040- 8428(00)00134-7.
28. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi.org/10.1016/ j.ccr.2005.03.003.
29. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14:4877-82; PMID:18676761; http://dx.doi.org/10.1158/1078-0432.CCR-07-5123.
30. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in nonsmall cell lung cancer. Cancer Res 2006; 66:7854-8; PMID:16912157; http://dx.doi.org/10.1158/0008-5472.CAN-06-1951.
31. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359:366-77; PMID:18596266; http://dx.doi.org/10.1056/NEJMoa0800668.
32. Prudkin L, Tang X, Wistuba II. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol 2009; 4:139-41; PMID:19096324; http://dx.doi.org/10.1097/JTO.0b013e3181915f92.
33. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37:1315-6; PMID:16258541; http://dx.doi.org/10.1038/ng1671.
34. Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, et al. Analysis of genetic variants in neversmokers with lung cancer facilitated by an Internetbased blood collection protocol: A preliminary report. Clin Cancer Res 2010; 16:755-63; PMID:20068085; http://dx.doi.org/10.1158/1078-0432.CCR-09-2437.
35. Vikis H, Sato M, James M, Wang D, Wang Y, Wang M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007; 67:4665-70; PMID:17510392; http://dx.doi.org/10.1158/0008-5472.CAN-07- 0217.
36. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12:6494-501; PMID:17085664; http://dx.doi.org/10.1158/1078-0432.CCR-06-1570.
37. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80; PMID:11423618; http://dx.doi.org/10. 1126/science. 1062538.
38. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-25; PMID:12204532; http://dx.doi.org/10.1016/S1535-6108(02)00096-X.
39. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105:2070-5; PMID:18227510; http://dx.doi.org/10.1073/pnas.0709662105.
40. Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008; 26:1182-4, author reply 1184-6; PMID:18309959; http://dx.doi.org/10.1200/JCO.2007.14.9039.
41. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14:7519-25; PMID:19010870; http://dx.doi.org/10.1158/1078-0432.CCR-08-0151.
42. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007; 4:1669-79, discussion 1680; PMID:17973572; http://dx.doi.org/10.1371/journal.pmed.0040315.
43. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67:11924-32; PMID:18089823; http://dx.doi.org/10.1158/0008- 5472.CAN-07-1885.
44. Jänne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007; 25:3936-44; PMID:17761977; http://dx.doi.org/10.1200/JCO.2007.11. 1336.
45. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-38; PMID:22452896; http://dx.doi.org/10.1016/S1470-2045(12)70087-6.
46. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119:3000-10; PMID:19759520.
47. Janjigian YY, Groen HJ, Horn L, Smit EF, Fu Y, Wang F, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. 2011.
48. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29:2346-56; PMID:20118985; http://dx.doi.org/10.1038/ onc.2009.526.
49. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462:1070-4; PMID:20033049; http://dx.doi.org/10.1038/nature08622.
50. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012; 2:934-47; PMID:22961667; http://dx.doi.org/10.1158/2159- 8290.CD-12-0103.
51. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69:3256-61; PMID:19351834; http://dx.doi.org/10.1158/0008-5472.CAN-08-4055.
52. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 2010; 107:6459-64; PMID:20308550; http://dx.doi.org/10.1073/pnas.0911188107.
53. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10. 1126/science. 1141478.
54. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1:352-65; PMID:22145099; http://dx.doi.org/10. 1158/2159-8290.CD-11-0106.
55. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012; 109:E2127-33; PMID:22773810; http://dx.doi.org/10.1073/pnas. 1203530109.
56. Nunes-Xavier C, Romá-Mateo C, Ríos P, Tárrega C, Cejudo-Marín R, Tabernero L, et al. Dualspecificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 2011; 11:109-32; PMID:21288197; http://dx.doi.org/10.2174/187152011794941190.
57. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, et al. A novel classification of lung cancer into molecular subtypes. PLoS One 2012; 7:e31906; PMID:22363766; http://dx.doi.org/10.1371/journal. pone.0031906.
58. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932-7; PMID:18093943; http://dx.doi.org/10.1073/pnas.0710370104.
59. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68:9479-87; PMID:19010923; http://dx.doi.org/10.1158/0008-5472.CAN-08-1643.
60. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 2011; 17:2260-9; PMID:21220474; http://dx.doi.org/10.1158/1078-0432.CCR-10-1993.
61. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77-88; PMID:20129249; http://dx.doi.org/10.1016/j.ccr. 2009.11.022.
62. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008; 14:6092-6; PMID:18829487; http://dx.doi.org/10.1158/1078-0432. CCR-08-0332.
63. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, et al. Rationale and design of MARQUEE: A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 2012; 13:391-5; PMID:22440336; http://dx.doi.org/10.1016/j.cllc.2012.01.003.
64. Sharma N, Adjei AA. In the clinic: Ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol 2011; 3(Suppl):S37-50; PMID:22128287; http://dx.doi.org/10.1177/1758834011423403.
65. Belani CP, Goss G, Blumenschein G Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 2012; 38:173-84; PMID:21715100; http://dx.doi.org/10.1016/j. ctrv.2011.05.009.
66. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009; 4:e7273; PMID:19806209; http://dx.doi.org/10.1371/journal. pone.0007273.
67. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009; 69:6871-8; PMID:19671800; http://dx.doi.org/10.1158/0008-5472.CAN-08-4490.
68. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007; 26:3909-19; PMID:17325667; http://dx.doi.org/10.1038/sj.onc.1210173.
69. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44:852-60; PMID:22751098; http://dx.doi.org/10.1038/ng.2330.
70. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2:922-33; PMID:22956644; http://dx.doi.org/10. 1158/2159-8290.CD-12-0108.
71. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFRdirected therapeutic antibody cetuximab. Sci Transl Med 2011; 3:99ra86; PMID:21900593; http://dx.doi.org/10.1126/scitranslmed.3002442.
72. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011; 12:715-23; PMID:21772280; http://dx.doi.org/10. 1038/ni.2060.
73. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011; 471:523-6; PMID:21430781; http://dx.doi.org/10.1038/nature09870.
74. Workman P, Clarke PA. Resisting targeted therapy: Fifty ways to leave your EGFR. Cancer Cell 2011; 19:437-40; PMID:21481786; http://dx.doi.org/10. 1016/j.ccr.2011.03.020.
75. Plummer R. Poly(ADP-ribose) polymerase inhibition: A new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 2011; 13:218; PMID:21884642; http://dx.doi.org/10.1186/bcr2877.
76. Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res 2012; 72:4796-806; PMID:22987487; http://dx.doi.org/10.1158/0008-5472.CAN-12- 1287.
77. Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower MC, et al. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. PLoS One 2011; 6:e24148; PMID:21912620; http://dx.doi.org/10.1371/journal.pone.0024148.
78. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011; 17:1160-8; PMID:21233402; http://dx.doi.org/10.1158/1078-0432.CCR-10-2158.
79. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17:1169-80; PMID:21248300; http://dx.doi.org/10. 1158/1078-0432.CCR-10-2277.
80. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006; 355:213-5; PMID:16837691; http://dx.doi.org/10.1056/NEJMc053610.
81. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, et al. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer 2010; 11:E1-4; PMID:20837450; http://dx.doi.org/10.3816/CLC.2010.n.046.
82. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19:754-64; PMID:21665149; http://dx.doi.org/10.1016/j.ccr.2011.04.019.
83. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011; 6:1152-61; PMID:21597390; http://dx.doi.org/10.1097/JTO. 0b013e318216ee52.
84. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr., Badve S, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24-phenotype. BMC Cancer 2010; 10:411; PMID:20691079; http://dx.doi.org/10.1186/1471-2407-10-411.
85. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008; 3:e2637; PMID:18612434; http://dx.doi.org/10.1371/journal.pone.0002637.
86. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005; 11:8686-98; PMID:16361555; http://dx.doi.org/10.1158/1078-0432.CCR-05- 1492.
87. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66:944-50; PMID:16424029; http://dx.doi.org/10.1158/0008-5472.CAN-05-1988.
88. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010; 10:219-22; PMID:20592490; http://dx.doi.org/10.4161/cbt.10.3.12548.
89. Ogawa T, Liggett TE, Melnikov AA, Monitto CL, Kusuke D, Shiga K, et al. Methylation of deathassociated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle 2012; 11:1656-63; PMID:22487682; http://dx.doi.org/10.4161/cc.20120.
90. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69-80; PMID:20371346; http://dx.doi.org/10.1016/j.cell.2010.02. 027.
91. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500-4; PMID:22763439; http://dx.doi.org/10.1038/ nature11183.
92. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growthfactor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505-9; PMID:22763448; http://dx.doi.org/10.1038/ nature11249.
93. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18:521-8; PMID:22426421; http://dx.doi.org/10.1038/nm.2713.
94. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7; PMID:10728703.
95. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272:2927-35; PMID:9006938; http://dx.doi.org/10.1074/jbc.272.5.2927.
96. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990; 87:8602-6; PMID:2236070; http://dx.doi.org/10.1073/pnas.87.21.8602.
97. Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation. Eur Respir J 2011; 37:624-31; PMID:20595147; http://dx.doi.org/10.1183/09031936.00195609.
98. Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012; 2:450-7; PMID:22588882; http://dx.doi.org/10.1158/2159-8290.CD-11-0287.
99. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-24; PMID:16282176; http://dx.doi.org/10. 1056/NEJMoa051918.
100. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351:2883; PMID:15625347; http://dx.doi.org/10.1056/NEJM200412303512724.
101. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, et al. Absence of EGFR mutation in the kinase domain in common human cancers besides nonsmall cell lung cancer. Int J Cancer 2005; 113:510-1; PMID:15455340; http://dx.doi.org/10. 1002/ijc.20591.
102. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A 1991; 88:7792-6; PMID:1715580; http://dx.doi.org/10.1073/pnas.88.17.7792.
103. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001; 92:1331-46; PMID:11571750; http://dx.doi.org/10.1002/1097- 0142(20010901)92:5<1331::AIDCNCR1455> 3.0.CO;2-M.
104. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B, et al. Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51:147-52; PMID:1434639; http://dx.doi.org/10.1002/jso.2930510304.
105. Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77:1352-4; PMID:2276016; http://dx.doi.org/10.1002/bjs.1800771211.
106. Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010; 39:601-13; PMID:20951919; http://dx.doi.org/10.1016/j.gtc.2010.08.017.
107. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39:1348-54; PMID:12826036; http://dx.doi.org/10.1016/ S0959-8049(03)00235-1.
108. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38:2258-64; PMID:12441262; http://dx.doi.org/10.1016/S0959-8049(02)00234-4.
109. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, betacatenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 2004; 10:3069-75; PMID:15131045; http://dx.doi.org/10.1158/1078-0432.CCR-03-0462.
110. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives. Ann Oncol 2005; 16:189-94; PMID:15668269; http://dx.doi.org/10.1093/annonc/mdi057.
111. Holubec L, Liska V, Matejka VM, Fiala O, Dreslerova J, Mrazkova P, et al. The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 2012; 32:4007-11; PMID:22993351.
112. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: Focus on panitumumab. Biologics 2008; 2:223-8; PMID:19707356.
113. Krasinskas AM. EGFR Signaling in Colorectal Carcinoma. Patholog Res Int 2011; 2011:932932; PMID:21403829; http://dx.doi.org/10.4061/2011/932932.
114. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10; PMID:15677699; http://dx.doi.org/10.1200/JCO.2005.08.037.
115. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025.
116. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579-84; PMID:8339264.
117. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998; 90:1080-7; PMID:9672256; http://dx.doi.org/10.1093/jnci/90.14.1080.
118. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78:1284-92; PMID:8826952; http://dx.doi.org/10.1002/(SICI) 1097-0142(19960915)78:6<1284::AIDCNCR17> 3.0.CO;2-X.
119. Thomas SM, Zeng Q, Epperly MW, Gooding WE, Pastan I, Wang QC, et al. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38. Clin Cancer Res 2004; 10:7079-87; PMID:15501988; http://dx.doi.org/10.1158/1078-0432.CCR-04-0587.
120. Udayachander M, Dean CJ, Meenakshi AN, Sivakumar N, Babu PB, Sivakumar J. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor. Hum Antibodies 1997; 8:60-4; PMID:9289389.
121. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27; PMID:18784101; http://dx.doi.org/10.1056/NEJMoa0802656.
122. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-7; PMID:17538161; http://dx.doi.org/10.1200/JCO.2006.06.7447.
123. Kundu SK, Nestor M. Targeted therapy in head and neck cancer. Tumour Biol 2012; 33:707-21; PMID:22373581; http://dx.doi.org/10.1007/s13277-012-0350-2.
124. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor
125. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10. 1056/NEJMoa0804385.
126. Oliveira-Cunha M, Hadfield KD, Siriwardena AK, Newman W. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas 2012; 41:428-34; PMID:22422135; http://dx.doi.org/10.1097/MPA.0b013e3182327a03.
127. Lüttges J, Reinecke-Lüthge A, Möllmann B, Menke MA, Clemens A, Klimpfinger M, et al. Duct changes and K-ras mutations in the disease-free pancreas: Analysis of type, age relation and spatial distribution. Virchows Arch 1999; 435:461-8; PMID:10592048; http://dx.doi.org/10.1007/ s004280050428.
128. Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 2011; 121:4572-8; PMID:22133881; http://dx.doi.org/10.1172/JCI57131.
129. De Lisle RC, Logsdon CD. Pancreatic acinar cells in culture: Expression of acinar and ductal antigens in a growth-related manner. Eur J Cell Biol 1990; 51:64-75; PMID:2184038.
130. Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012; 22:304-17; PMID:22975374; http://dx.doi.org/10. 1016/j.ccr.2012.07.024.
131. Korc M, Friess H, Yamanaka Y, Kobrin MS, Buchler M, Beger HG. Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma. Gut 1994; 35:1468-73; PMID:7959207; http://dx.doi.org/10.1136/gut.35.10.1468.
132. Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012; 22:318-30; PMID:22975375; http://dx.doi.org/10.1016/j.ccr.2012.08.001.
133. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J, et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009; 137:1072-82, 1082, e1-6; PMID:19501586; http://dx.doi.org/10.1053/j.gastro.2009. 05.052.
134. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6; PMID:17452677; http://dx.doi.org/10. 1200/JCO.2006.07.9525.